Skip to Main Content

Paper Details

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells.
Oncotarget
14
2020
Akt, CDK4, CDK4/6, CDK6, D-cyclin kinases, ER+, PI3K, PIK3CA, PIK3CA mutations, PIK3CA-mutant, PIK3CA-mutant ER+ breast cancer, PIM, PIM kinase, PIM kinases, Rb, S6, TSC2, abemaciclib, anti, cancer, cancer cells, mTOR, tumor

Datasets

Release 1.2